Antiangiogenesis in haematological malignancies

British Journal of Haematology

Volumn 143, Issue 5, 2008, Pages 622-631

  Li, William W ^a   Hutnik, Michelle ^a   Gehr, Gerald ^a,b,c  

^a The Angiogenesis Foundation   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Manchester VA Medical Center   (United States)

Author keywords

Angiogenesis; Antiangiogenesis; Haematogenous malignancies; Leukaemia; Vascular endothelial growth factor

Indexed keywords

7 HYDROXYSTAUROSPORINE; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; CYTARABINE; CYTOKINE ANTIBODY; CYTOTOXIC AGENT; DAUNORUBICIN; DEFOROLIMUS; DEXAMETHASONE; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; HOMOHARRINGTONINE; IDARUBICIN; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOXANTRONE; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BONE MARROW; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; HEALTH STATUS; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LUNG TOXICITY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOMA; NEUROPATHY; PRIORITY JOURNAL; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; BONE MARROW CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55949107650     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07372.x     Document Type: Review

References (78)

1. Aguayo, A., Estey, E., Kantarjian, H., Mansouri, T., Gidel, C., Keating, M., Giles, F., Estrov, Z., Barlogie, B. Albitar, M. (1999) Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 94, 3717 3721.
2. Aguayo, A., Kantarjian, H.M., Estey, E.H., Giles, F.J., Verstovsek, S., Manshouri, T., Gidel, C., O'Brien, S., Keating, M.J. Albitar, M. (2002) Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer, 95, 1923 1930.
3. Anargyrou, K., Dimopoulos, M.A., Sezer, O. Terpos, E. (2008) Novel anti-myeloma agents and angiogenesis. Leukaemia & Lymphoma, 49, 677 689.
4. Attar, E.C., De Angelo, D.J., Supko, J.G., D'Amato, F., Zahrieh, D., Sirulnik, A., Wadleigh, M., Ballen, K.K., McAfee, S., Miller, K.B., Levine, J., Galinsky, I., Trehu, E.G., Schenkein, D., Neuberg, D., Stone, R.M. Amrein, P.C. (2008) Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clinical Cancer Research, 14, 1446 1454.
5. Avramis, I.A., Panosyan, E.H., Dorey, F., Holcenberg, J.S. Avramis, V.I. (2006) Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962. Clinical Cancer Research, 12, 6978 6984.
6. Banks, R.E., Forbes, M.A., Kinsey, S.E., Stanley, A., Ingham, E., Walters, C. Selby, P.J. (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. British Journal of Cancer, 77, 956 964.
7. Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D. Tricot, G. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98, 492 494.
8. Barr, P., Fu, P., Lazarus, H., Kane, D., Meyerson, H., Hartman, P., Reyes, R., Creger, R., Stear, K., Laughlin, M., Tse, W. Cooper, B. (2007) Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leukaemia & Lymphoma, 48, 1940 1949.
9. Bellamy, W.T., Richter, L., Frutiger, Y. Grogan, T.M. (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research, 59, 728 733.
10. Bellamy, W.T., Richter, L., Sirjani, D., Roxas, C., Glinsmann-Gibson, B., Frutiger, Y., Grogan, T.M. List, A.F. (2001) Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood, 97, 1427 1434.
11. de Bont, E.S., Fidler, V., Meeuwsen, T., Scherpen, F., Hahlen, K. Kamps, W.A. (2002) Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clinical Cancer Research, 8, 2856 2861.
12. D'Amato, R.J., Loughnan, M.S., Flynn, E. Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 4082 4085.
13. Dias, S., Shmelkov, S.V., Lam, G. Rafii, S. (2002) VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood, 99, 2532 2540.
14. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123 2132.
15. Dong, X., Han, Z.C. Yang, R. (2007) Angiogenesis and antiangiogenic therapy in hematologic malignancies. Critical Reviews in Oncology/hematology, 62, 105 118.
16. Dormond, O., Madsen, J.C. Briscoe, D.M. (2007) The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. Journal of Biological Chemistry, 282, 23679 23686.
17. Drexler, H.G. (1996) Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia, 10, 588 599.
18. Faderl, S., Do, K.A., Johnson, M.M., Keating, M., O'Brien, S., Jilani, I., Ferrajoli, A., Ravandi-Kashani, F., Aguilar, C., Dey, A., Thomas, D.A., Giles, F.J., Kantarjian, H.M. Albitar, M. (2005) Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood, 106, 4303 4307.
19. Ferrajoli, A., Lee, B.N., Schlette, E.J., O'Brien, S.M., Gao, H., Wen, S., Wierda, W.G., Estrov, Z., Faderl, S.H., Cohen, E.N., Li, C., Reuben, J.M. Keating, M.J. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 111, 5291 5297.
20. Ferrara, N., Hillan, K.J., Gerber, H.P. Novotny, W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews. Drug Discovery, 3, 391 400.
21. Fiedler, W., Graeven, U., Ergun, S., Verago, S., Kilic, N., Stockschlader, M. Hossfeld, D.K. (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 89, 1870 1875.
22. Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Duhrsen, U., Flasshove, M., Ottmann, O.G., Jung, W., Cavalli, F., Kuse, R., Thomalla, J., Serve, H., O'Farrell, A.M., Jacobs, M., Brega, N.M., Scigalla, P., Hossfeld, D.K. Berdel, W.E. (2003) A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood, 102, 2763 2767.
23. Fiedler, W., Serve, H., Dohner, H., Schwittay, M., Ottmann, O.G., O'Farrell, A.M., Bello, C.L., Allred, R., Manning, W.C., Cherrington, J.M., Louie, S.G., Hong, W., Brega, N.M., Massimini, G., Scigalla, P., Berdel, W.E. Hossfeld, D.K. (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 105, 986 993.
24. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285, 1182 1186.
25. Folkman, J. (2007) Is angiogenesis an organizing principle in biology and medicine? Journal of Pediatric Surgery, 42, 1 11.
26. Folkman, J., Browder, T. Palmblad, J. (2001) Angiogenesis research: guidelines for translation to clinical application. Thrombosis and Haemostasis, 86, 23 33.
27. Frater, J.L., Kay, N.E., Goolsby, C.L., Crawford, S.E., Dewald, G.W. Peterson, L.C. (2008) Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. Diagnostic Pathology, 3, 16.
28. Gerber, H.P. Ferrara, N. (2003) The role of VEGF in normal and neoplastic hematopoiesis. Journal of Molecular Medicine, 81, 20 31.
29. Giles, F.J. (2002) The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Williston Park), 16, 23 29.
30. Giles, F.J. Albitar, M. (2005) Mammalian target of rapamycin as a therapeutic target in leukemia. Current Molecular Medicine, 5, 653 661.
31. Hu, Q., Dey, A.L., Yang, Y., Shen, Y., Jilani, I.B., Estey, E.H., Kantarjian, H.M., Giles, F.J. Albitar, M. (2004) Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer, 100, 1884 1891.
32. Hussong, J.W., Rodgers, G.M. Shami, P.J. (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 95, 309 313.
33. Kane, R.C., Farrell, A.T., Sridhara, R. Pazdur, R. (2006) United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clinical Cancer Research, 12, 2955 2960.
34. Karp, J.E., Gojo, I., Pili, R., Gocke, C.D., Greer, J., Guo, C., Qian, D., Morris, L., Tidwell, M., Chen, H. Zwiebel, J. (2004) Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research, 10, 3577 3585.
35. Keith, T., Araki, Y., Ohyagi, M., Hasegawa, M., Yamamoto, K., Kurata, M., Nakagawa, Y., Suzuki, K. Kitagawa, M. (2007) Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. British Journal Haematology, 137, 206 215.
36. Kessler, T., Fehrmann, F., Bieker, R., Berdel, W.E. Mesters, R.M. (2007) Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Current Drug Targets, 8, 257 268.
37. Knapper, S. (2007) FLT3 inhibition in acute myeloid leukaemia. British Journal Haematology, 138, 687 699.
38. Koomagi, R., Zintl, F., Sauerbrey, A. Volm, M. (2001) Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clinical Cancer Research, 7, 3381 3384.
39. List, A.F. (2001) Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist, 6 (Suppl. 5 24 31.
40. List, A., Kurtin, S., Roe, D.J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R. Zeldis, J.B. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. New England Journal of Medicine, 352, 549 557.
41. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J. Knight, R. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine, 355, 1456 1465.
42. Lopes de Menezes, D.E., Peng, J., Garrett, E.N., Louie, S.G., Lee, S.H., Wiesmann, M., Tang, Y., Shephard, L., Goldbeck, C., Oei, Y., Ye, H., Aukerman, S.L. Heise, C. (2005) CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clinical Cancer Research, 11, 5281 5291.
43. Ma, X., Does, M., Raza, A. Mayne, S.T. (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer, 109, 1536 1542.
44. Martelli, A.M., Tazzari, P.L., Evangelisti, C., Chiarini, F., Blalock, W.L., Billi, A.M., Manzoli, L., McCubrey, J.A. Cocco, L. (2007) Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Current Medicinal Chemistry, 14, 2009 2023.
45. Nimer, S.D. (2008) Myelodysplastic syndromes. Blood, 111, 4841 4851.
46. Padro, T., Ruiz, S., Bieker, R., Burger, H., Steins, M., Kienast, J., Buchner, T., Berdel, W.E. Mesters, R.M. (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, 95, 2637 2644.
47. Pellagatti, A., Jadersten, M., Forsblom, A.M., Cattan, H., Christensson, B., Emanuelsson, E.K., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., Wainscoat, J.S., Boultwood, J. Hellstrom-Lindberg, E. (2007) Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proceedings of the National Academy of Sciences of the United States of America, 104, 11406 11411.
48. Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E. Folkman, J. (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. American Journal of Pathology, 150, 815 821.
49. Podar, K. Anderson, K.C. (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood, 105, 1383 1395.
50. Pruneri, G., Bertolini, F., Soligo, D., Carboni, N., Cortelezzi, A., Ferrucci, P.F., Buffa, R., Lambertenghi-Deliliers, G. Pezzella, F. (1999) Angiogenesis in myelodysplastic syndromes. British Journal of Cancer, 81, 1398 1401.
51. Quesada, A.R., Medina, M.A. Alba, E. (2007) Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays, 29, 1159 1168.
52. Quintas-Cardama, A., Kantarjian, H., Garcia-Manero, G., O'Brien, S., Faderl, S., Estrov, Z., Giles, F., Murgo, A., Ladie, N., Verstovsek, S. Cortes, J. (2007) Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer, 109, 248 255.
53. Rajkumar, S.V., Mesa, R.A. Tefferi, A. (2002) A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. Journal of Hematotherapy & Stem Cell Research, 11, 33 47.
54. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431 436.
55. Rajkumar, S.V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J.B. Blade, J. (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology, 26, 2171 2177.
56. Recher, C., Beyne-Rauzy, O., Demur, C., Chicanne, G., Dos Santos, C., Mas, V.M., Benzaquen, D., Laurent, G., Huguet, F. Payrastre, B. (2005) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 105, 2527 2534.
57. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063 3067.
58. Rizzieri, D.A., Feldman, E., Dipersio, J.F., Gabrail, N., Stock, W., Strair, R., Rivera, V.M., Albitar, M., Bedrosian, C.L. Giles, F.J. (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research, 14, 2756 2762.
59. Roboz, G.J., Giles, F.J., List, A.F., Cortes, J.E., Carlin, R., Kowalski, M., Bilic, S., Masson, E., Rosamilia, M., Schuster, M.W., Laurent, D. Feldman, E.J. (2006) Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia, 20, 952 957.
60. Roccaro, A.M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., Dammacco, F., Richardson, P.G. Anderson, K.C. (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Research, 66, 184 191.
61. Roy, A.M., Tiwari, K.N., Parker, W.B., Secrist, III., J.A., Li, R. Qu, Z. (2006) Antiangiogenic activity of 4′-thio-beta-D- arabinofuranosylcytosine. Molecular Cancer Therapeutics, 5, 2218 2224.
62. Santos, S.C. Dias, S. (2004) Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood, 103, 3883 3889.
63. Schaefer, C., Krause, M., Fuhrhop, I., Schroeder, M., Algenstaedt, P., Fiedler, W., Ruther, W. Hansen-Algenstaedt, N. (2008) Time-course-dependent microvascular alterations in a model of myeloid leukemia in vivo. Leukemia, 22, 59 65.
64. Sezer, O., Niemoller, K., Eucker, J., Jakob, C., Kaufmann, O., Zavrski, I., Dietel, M. Possinger, K. (2000) Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Annals of Hematology, 79, 574 577.
65. Shin, D.H., Chun, Y.S., Lee, D.S., Huang, L.E. Park, J.W. (2008) Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood, 111, 3131 3136.
66. Sillaber, C., Mayerhofer, M., Bohm, A., Vales, A., Gruze, A., Aichberger, K.J., Esterbauer, H., Pfeilstocker, M., Sperr, W.R., Pickl, W.F., Haas, O.A. Valent, P. (2008) Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. European Journal of Clinical Investigation, 38, 43 52.
67. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565 1571.
68. Sipkins, D.A., Wei, X., Wu, J.W., Runnels, J.M., Cote, D., Means, T.K., Luster, A.D., Scadden, D.T. Lin, C.P. (2005) In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature, 435, 969 973.
69. Steins, M.B., Bieker, R., Padro, T., Kessler, T., Kienast, J., Berdel, W.E. Mesters, R.M. (2003) Thalidomide for the treatment of acute myeloid leukemia. Leukaemia & Lymphoma, 44, 1489 1493.
70. Strupp, C., Germing, U., Aivado, M., Misgeld, E., Haas, R. Gattermann, N. (2002) Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia, 16, 1 6.
71. Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F. Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. British Journal Haematology, 87, 503 508.
72. Vales, A., Kondo, R., Aichberger, K.J., Mayerhofer, M., Kainz, B., Sperr, W.R., Sillaber, C., Jager, U. Valent, P. (2007) Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leukaemia & Lymphoma, 48, 1997 2007.
73. Veiga, J.P., Costa, L.F., Sallan, S.E., Nadler, L.M. Cardoso, A.A. (2006) Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Experimental Hematology, 34, 610 621.
74. Verstovsek, S., Kantarjian, H., Manshouri, T., Cortes, J., Giles, F.J., Rogers, A. Albitar, M. (2002) Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood, 99, 2265 2267.
75. Wang, M., Knight, R., Dimopoulos, M., Siegel, D., Rajkumar, S.V., Facon, T., Yu, Z., Zeldis, J., Olesnyckyj, M. Weber, D.M. (2006) Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma. Journal of Clinical Oncology (Meeting Abstracts), 24, 7522.
76. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133 2142.
77. Williams, S., Pettaway, C., Song, R., Papandreou, C., Logothetis, C. McConkey, D.J. (2003) Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Molecular Cancer Therapeutics, 2, 835 843.
78. Zahiragic, L., Schliemann, C., Bieker, R., Thoennissen, N.H., Burow, K., Kramer, C., Zuhlsdorf, M., Berdel, W.E. Mesters, R.M. (2007) Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia, 21, 1310 1312.